drugset / Trial / NCT00610714

AZD0530 Phase II Study in Patients With Advanced Ovarian Cancer

NCT00610714

Phase 2 Completed 211 enrolled AstraZeneca
RandomizedParallel-groupTriple-blindTreatment

Summary

The main purpose of this study is to determine if AZD0530 can improve the efficacy of standard chemotherapy for the treatment of ovarian cancer

Timeline

Start
2008-04
Primary completion
2009-08
Completion
2012-01

Drugs

EvaluationDrugModalityDoseRoute
Subject saracatinib Small molecule
Background Carboplatin Small molecule Intravenous
Background Paclitaxel Small molecule Intravenous

Indications